Matt Hitchings

Matt Hitchings,

Assistant Professor

Department: PHHP-COM BIOSTATISTICS
Business Phone: (352) 294-1945
Business Email: mhitchings@ufl.edu

Teaching Profile

Courses Taught
2021
PHC6059 Introduction to Applied Survival Analysis

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0003-2327-3557

Areas of Interest
  • Clinical Trials Design & Analysis
  • Emerging infectious disease
  • Infectious Diesease
  • Vaccination

Publications

2022
Effectiveness of a monthly schedule of follow-up for the treatment of uncomplicated severe acute malnutrition in Sokoto, Nigeria: A cluster randomized crossover trial
PLOS Medicine. 19(3) [DOI] 10.1371/journal.pmed.1003923. [PMID] 35231024.
2022
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
The Lancet. Infectious diseases. [DOI] 10.1016/S1473-3099(22)00140-2. [PMID] 35366959.
2022
EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil.
Trials. 23(1) [DOI] 10.1186/s13063-022-05997-4. [PMID] 35236394.
2022
Structural factors contributing to SARS-CoV-2 infection risk in the urban slum setting.
medRxiv : the preprint server for health sciences. [DOI] 10.1101/2022.02.13.22270856. [PMID] 35194620.
2022
Use of recently vaccinated individuals to detect bias in test-negative case-control studies of COVID-19 vaccine effectiveness.
Epidemiology (Cambridge, Mass.). [DOI] 10.1097/EDE.0000000000001484. [PMID] 35384900.
2021
Effect of specific non-pharmaceutical intervention policies on SARS-CoV-2 transmission in the counties of the United States.
Nature communications. 12(1) [DOI] 10.1038/s41467-021-23865-8. [PMID] 34117244.
2021
Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo
Nature Communications. 12(1) [DOI] 10.1038/s41467-021-26459-6. [PMID] 34711813.
2021
Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study
The Lancet Regional Health – Americas. 1 [DOI] 10.1016/j.lana.2021.100025. [PMID] 34386791.
2021
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study.
BMJ (Clinical research ed.). 374 [DOI] 10.1136/bmj.n2015. [PMID] 34417194.
2021
Risk Factors for Healthcare Personnel Infection With Endemic Coronaviruses (HKU1, OC43, NL63, 229E): Results from the Respiratory Protection Effectiveness Clinical Trial (ResPECT).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 73(11):e4428-e4432 [DOI] 10.1093/cid/ciaa900. [PMID] 32645144.
2021
The Usefulness of the Test-Positive Proportion of Severe Acute Respiratory Syndrome Coronavirus 2 as a Surveillance Tool.
American journal of epidemiology. 190(7):1396-1405 [DOI] 10.1093/aje/kwab023. [PMID] 33576387.
2020
A mixture model to assess the the immunogenicity of an oral rotavirus vaccine among healthy infants in Niger.
Vaccine. 38(51):8161-8166 [DOI] 10.1016/j.vaccine.2020.10.079. [PMID] 33162202.
2020
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.
Nature communications. 11(1) [DOI] 10.1038/s41467-020-18450-4. [PMID] 32943637.
2020
Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials.
Vaccine. 38(46):7213-7216 [DOI] 10.1016/j.vaccine.2020.09.031. [PMID] 33012602.
2020
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.
Vaccine. 38(31):4877-4884 [DOI] 10.1016/j.vaccine.2020.04.066. [PMID] 32499066.
2019
Analysis of a meningococcal meningitis outbreak in Niger – potential effectiveness of reactive prophylaxis
PLOS Neglected Tropical Diseases. 13(3) [DOI] 10.1371/journal.pntd.0007077. [PMID] 30856166.
2019
Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection.
American journal of epidemiology. 188(2):467-474 [DOI] 10.1093/aje/kwy239. [PMID] 30329134.
2019
Linear growth faltering and the role of weight attainment: Prospective analysis of young children recovering from severe wasting in Niger
Maternal & Child Nutrition. 15(4) [DOI] 10.1111/mcn.12817. [PMID] 30903806.
2018
Competing Effects of Indirect Protection and Clustering on the Power of Cluster-Randomized Controlled Vaccine Trials.
American journal of epidemiology. 187(8):1763-1771 [DOI] 10.1093/aje/kwy047. [PMID] 29522080.
2018
Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials.
Clinical trials (London, England). 15(2):207-211 [DOI] 10.1177/1740774517752671. [PMID] 29374974.
2018
Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial
PLOS Medicine. 15(6) [DOI] 10.1371/journal.pmed.1002593. [PMID] 29944651.
2017
Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial.
Trials. 18(1) [DOI] 10.1186/s13063-017-2028-y. [PMID] 28646924.
2017
Using simulation to aid trial design: Ring-vaccination trials.
PLoS neglected tropical diseases. 11(3) [DOI] 10.1371/journal.pntd.0005470. [PMID] 28328984.
Analysis of a meningococcal meningitis outbreak in Niger – potential effectiveness of reactive prophylaxis
. [DOI] 10.1101/496299.
Change in COVID-19 risk over time following vaccination with CoronaVac: A test-negative case-control study
. [DOI] 10.1101/2021.12.23.21268335. [PMID] 34988559.

Grants

Apr 2022 ACTIVE
RAPID: Statistical inference of incidence of SARS-CoV-2 in the US using multiple data streams to identify levels of immunity and the impact of non-pharmaceutical interventions
Role: Co-Project Director/Principal Investigator
Funding: NATL SCIENCE FOU
Mar 2022 ACTIVE
Estimating the incidence of dengue in travelers from non-endemic countries
Role: Co-Investigator
Funding: Merck Sharp & Dohme
Jan 2022 ACTIVE
IPA for Matthew Hitchings 2022
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Aug 2021 ACTIVE
Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats
Role: Co-Investigator
Funding: EMORY UNIV via NATL INST OF HLTH NIAID

Contact Details

Phones:
Business:
(352) 294-1945
Emails:
Business:
mhitchings@ufl.edu
Addresses:
Business Mailing:
PO BOX 117450
GAINESVILLE FL 326117450